» Articles » PMID: 34452428

CARs-A New Perspective to HCMV Treatment

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2021 Aug 28
PMID 34452428
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Human cytomegalovirus (HCMV), by primary infection or reactivation, represents a great risk for immune-suppressed or compromised patients. In immunocompetent humans, the immune system suppresses the spread of HCMV during an infection, resulting in a mostly asymptomatic or mild course of the disease, whereas in immune suppressed patients, the compromised host immune response cannot control the viral infection. Multiple viral immunomodulatory mechanisms additionally contribute to immune evasion. Use of chimeric antigen receptors (CARs), a treatment strategy adapted from cancer immunotherapy, is investigated for possible application to combat HCMV and other infections in immunocompromised patients. The administration of CAR T-cells directed against HCMV antigens can bypass viral immune evasion and may complement existing treatment methods. This review gives a short overview of HCMV, the obstacles of current treatment options as well as a brief introduction to CARs and the current research situation on CAR T-cells against HCMV.

Citing Articles

Evaluation of Bispecific T-Cell Engagers Targeting Murine Cytomegalovirus.

Menschikowski H, Bednar C, Kubel S, Hermann M, Bauer L, Thomas M Viruses. 2024; 16(6).

PMID: 38932161 PMC: 11209133. DOI: 10.3390/v16060869.


Human cytomegalovirus UL23 exploits PD-L1 inhibitory signaling pathway to evade T cell-mediated cytotoxicity.

Yuan Q, Fan Z, Huang W, Huo X, Yang X, Ran Y mBio. 2024; 15(7):e0119124.

PMID: 38829126 PMC: 11253622. DOI: 10.1128/mbio.01191-24.


Enhanced Immunomodulatory Effects of Thymosin-Alpha-1 in Combination with Polyanionic Carbosilane Dendrimers against HCMV Infection.

De La Sierra Espinar-Buitrago M, Magro-Lopez E, Vazquez-Alejo E, Munoz-Fernandez M Int J Mol Sci. 2024; 25(4).

PMID: 38396631 PMC: 10887890. DOI: 10.3390/ijms25041952.


CAR Immunotherapy for the treatment of infectious diseases: a systematic review.

Morte-Romea E, Pesini C, Pellejero-Sagastizabal G, Letona-Gimenez S, Martinez-Lostao L, Aranda S Front Immunol. 2024; 15:1289303.

PMID: 38352878 PMC: 10861799. DOI: 10.3389/fimmu.2024.1289303.


A Genetically Encoded Dark-to-Bright Biosensor for Visualisation of Granzyme-Mediated Cytotoxicity.

Bednar C, Kubel S, Cordsmeier A, Scholz B, Menschikowski H, Ensser A Int J Mol Sci. 2023; 24(17).

PMID: 37686395 PMC: 10487497. DOI: 10.3390/ijms241713589.


References
1.
Slabik C, Kalbarczyk M, Danisch S, Zeidler R, Klawonn F, Volk V . CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease. Mol Ther Oncolytics. 2020; 18:504-524. PMC: 7479496. DOI: 10.1016/j.omto.2020.08.005. View

2.
Majeed A, Latif A, Kapoor V, Sohail A, Florita C, Georgescu A . Resistant Cytomegalovirus Infection in Solid-organ Transplantation: Single-center Experience, Literature Review of Risk Factors, and Proposed Preventive Strategies. Transplant Proc. 2018; 50(10):3756-3762. DOI: 10.1016/j.transproceed.2018.02.091. View

3.
Riddell S, Walter B, Gilbert M, Greenberg P . Selective reconstitution of CD8+ cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones. Bone Marrow Transplant. 1994; 14 Suppl 4:S78-84. View

4.
Goodrum F . Human Cytomegalovirus Latency: Approaching the Gordian Knot. Annu Rev Virol. 2016; 3(1):333-357. PMC: 5514425. DOI: 10.1146/annurev-virology-110615-042422. View

5.
Gross G, Waks T, Eshhar Z . Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989; 86(24):10024-8. PMC: 298636. DOI: 10.1073/pnas.86.24.10024. View